P. Tomasini

F. Shepherd, P. Tomasini, M. Doherty, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The place of pemetrexed in the management of non-small-cell lung cancer patients

F. Barlesi, P. Tomasini, L. Greillier, 2013, Expert review of anticancer therapy.

Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors.

F. Barlesi, P. Tomasini, 2020, The Lancet. Oncology.

Prospective multi-center validation of the detection of ALK rearrangements of circulating tumor cells for non-invasive longitudinal management of patients with advanced non-small cell lung cancer.

C. Marquette, J. Thariat, J. Mazières, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Low lamin A expression in lung adenocarcinoma cells from pleural effusions is a pejorative factor associated with high number of metastatic sites and poor Performance status

N. Lévy, J. Micallef, P. Tomasini, 2017, PloS one.

Predictive Factors of Intracranial Response of Immune Checkpoint Inhibitors in Patients with Brain Metastasis from Non-Small Cell Lung Cancer

C. Mascaux, F. Barlesi, P. Tomasini, 2019, Journal of Cancer Therapy.

PGPM_A_267437 987..996

P. Tomasini, L. Greillier, A. Mogenet, 2021 .

Nivolumab plus ipilimumab in malignant pleural mesothelioma

P. Tomasini, L. Greillier, C. Travert, 2022, Expert review of anticancer therapy.

Failure of the Ottawa Score to Predict the Risk of Recurrent Venous Thromboembolism in Cancer Patients: The Prospective PREDICARE Cohort Study

A. Lamblin, S. Laporte, C. Chapelle, 2021, Thrombosis and Haemostasis.

Revisiting metronomic vinorelbine with mathematical modelling: a Phase I trial in lung cancer

F. Barlesi, P. Tomasini, J. Ciccolini, 2022, Cancer Chemotherapy and Pharmacology.

Severe Immune Checkpoint Inhibitor Toxicity Leading to ICU Admission in Patients With Solid Tumors.

P. Tomasini, M. Boucekine, J. Carvelli, 2022, American journal of clinical oncology.

Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance.

C. Escriu, P. Tomasini, K. Clark-Langone, 2020, NPJ precision oncology.

Stereotactic body radiation therapy (SBRT) as salvage treatment for early stage lung cancer with interstitial lung disease (ILD): An observational and exploratory case series of non-asian patients.

P. Tomasini, L. Padovani, L. Greillier, 2022, Respiratory medicine and research.

Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer

F. Barlesi, P. Tomasini, D. Barbolosi, 2019, Scientific Reports.

Immune Oncology Biomarkers in Lung Cancer: an Overview

F. Barlesi, P. Tomasini, L. Greillier, 2020, Current Oncology Reports.

Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy

F. Barlesi, P. Tomasini, F. Jean, 2017, Therapeutic advances in medical oncology.

Personalised medicine for nonsmall cell lung cancer

C. Mascaux, F. Barlesi, P. Tomasini, 2017, European Respiratory Review.

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.

P. Tomasini, N. Leighl, C. Labbé, 2016, The oncologist.

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.

J-L Pretet, I. Bièche, J. Solassol, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).

M. Tsao, F. Shepherd, S. Kamel‐Reid, 2017, Lung cancer.

New oncogenes drivers in lung cancer—new therapeutic targets

F. Barlesi, P. Tomasini, L. Greillier, 2016, Current Pulmonology Reports.

Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer.

Arnaud Boyer, F. Barlesi, P. Tomasini, 2018, Journal of thoracic disease.

First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety

T. Burns, D. Juric, R. Yaeger, 2022, Journal of Clinical Oncology.

Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data

F. Barlesi, P. Tomasini, D. Barbolosi, 2021, medRxiv.

Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data

F. Barlesi, P. Tomasini, D. Barbolosi, 2021, Cancers.

The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.

M. Tsao, F. Shepherd, S. Kamel‐Reid, 2018, Lung cancer.

Necitumumab for non-small cell lung cancer

F. Barlesi, P. Tomasini, L. Greillier, 2015, Expert opinion on biological therapy.

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

N. Girard, D. Planchard, J. Mazières, 2017, European Respiratory Journal.

Mechanistic modeling of brain metastases in NSCLC provides computational markers for personalized prediction of outcome

P. Tomasini, S. Benzekry, E. Simon, 2023, medRxiv.

[Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].

F. Barlesi, P. Tomasini, L. Greillier, 2011, Revue des maladies respiratoires.

Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer

N. André, E. Tabouret, P. Tomasini, 2022, Current oncology.

Functional status in older patients with lung cancer: an observational cohort study

F. Barlesi, P. Tomasini, P. Villani, 2022, Supportive Care in Cancer.

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors

N. Girard, J. Mazières, D. Moro-Sibilot, 2017, Oncotarget.

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).

J. Mazières, C. Mascaux, F. Barlesi, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Advanced non-squamous non-small-cell lung cancer: who and when should be biologically screened today? Tomorrow?

F. Barlesi, P. Tomasini, L. Greillier, 2013, Current Respiratory Care Reports.

Effects of Ethnicity on Outcomes of Patients With EGFR Mutation–Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection

M. Tsao, F. Shepherd, S. Kamel‐Reid, 2021, JTO clinical and research reports.

Solitary cystic mediastinal lymphangioma

F. Maldonado, P. Chanez, P. Tomasini, 2013, European Respiratory Review.

The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer

P. Tomasini, L. Greillier, A. Mogenet, 2021, Pharmacogenomics and personalized medicine.

Ipilimumab: its potential in non-small cell lung cancer

F. Barlesi, P. Tomasini, L. Greillier, 2012, Therapeutic advances in medical oncology.

Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.

C. Mascaux, F. Barlesi, P. Tomasini, 2019, Clinical lung cancer.

BIABooster: Online DNA Concentration and Size Profiling with a Limit of Detection of 10 fg/μL and Application to High-Sensitivity Characterization of Circulating Cell-Free DNA.

Frédéric Ginot, Aziz Zaanan, Aurélien Bancaud, 2018, Analytical chemistry.

387P Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study

D. Camidge, P. Tomasini, M. Dunbar, 2022, Annals of Oncology.

Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC).

N. Girard, D. Planchard, T. Ciuleanu, 2022, Journal of Clinical Oncology.

1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study

E. Felip, B. Cho, R. Knoblauch, 2021, Annals of Oncology.

Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance

A. Bergamaschi, F. Baehner, C. Escriu, 2020, npj Precision Oncology.

Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?

N. André, E. Pasquier, C. Mascaux, 2018, European Respiratory Review.

Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018.

J. Grellard, B. Clarisse, P. Tomasini, 2023, European journal of cancer.

Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes

C. Mascaux, F. Barlesi, P. Tomasini, 2016, Therapeutic advances in medical oncology.

OA15.04 Telisotuzumab Vedotin (teliso-v) Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer

D. Camidge, J. Goldman, P. Tomasini, 2021, Journal of Thoracic Oncology.

Comparative genomic analysis of primary tumors and paired brain metastases in lung cancer patients by whole exome sequencing: a pilot study

R. Soffietti, F. Barlesi, P. Tomasini, 2020, Oncotarget.

Acceptance, efficacy, and safety of COVID-19 vaccination in older patients with cancer

R. Charrel, S. Salas, P. Tomasini, 2022, Journal of Geriatric Oncology.

Anaphylactic reaction to pemetrexed: a case report.

F. Barlesi, P. Tomasini, D. Charpin, 2014, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients

N. André, C. Mascaux, F. Barlesi, 2017, Oncotarget.

[Immunotherapy adaptation in lung cancer during the COVID-19 pandemic].

P. Cannone, P. Tomasini, L. Greillier, 2021, Revue des maladies respiratoires.

Octogenarians treated for thoracic and lung cancers: Impact of comprehensive geriatric assessment.

F. Barlesi, P. Tomasini, P. Villani, 2020, Journal of geriatric oncology.

Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases

F. Barlesi, P. Tomasini, L. Greillier, 2019, Therapeutic advances in respiratory disease.

Feasibility and diagnostic accuracy of the Patient‐Reported Outcomes Measurement Information System (PROMIS) item banks for routine surveillance of sleep and fatigue problems in ambulatory cancer care

Geoffrey Liu, P. Tomasini, D. Howell, 2016, Cancer.

Older Patients Treated for Lung and Thoracic Cancers: Unplanned Hospitalizations and Overall Survival.

F. Barlesi, P. Tomasini, P. Villani, 2020, Clinical lung cancer.

Elderly selection on geriatric index assessment.

C. Mascaux, F. Barlesi, P. Tomasini, 2016, Annals of Translational Medicine.

Revisiting metronomic vinorelbine with mathematical modelling: a Phase I trial in lung cancer

F. Barlesi, P. Tomasini, J. Ciccolini, 2022, Cancer Chemotherapy and Pharmacology.

EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer

C. Mascaux, F. Barlesi, P. Tomasini, 2016, International journal of molecular sciences.

Early circulating tumor (ct) DNA dynamics and efficacy of lorlatinib: Analysis from the CROWN study.

A. Shaw, C. Chiu, B. Solomon, 2021 .

Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience

F. Barlesi, P. Tomasini, L. Greillier, 2016, Therapeutic advances in respiratory disease.

Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.

M. Tsao, F. Shepherd, S. Kamel‐Reid, 2019, Clinical lung cancer.

Computational modeling reveals dynamics of brain metastasis in non-small cell lung cancer and provides a tool for personalized therapy

F. Barlesi, P. Tomasini, D. Barbolosi, 2018, bioRxiv.

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice

J. Mosser, J. Mazières, G. Zalcman, 2017, European Respiratory Journal.

Abstract CT008: Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100

C. Dooms, J. Desai, R. Govindan, 2022, Cancer Research.

Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

A. Drilon, Keunchil Park, B. Solomon, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?

F. Barlesi, P. Tomasini, L. Greillier, 2019, Translational lung cancer research.

Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.

A. Drilon, J. Mazières, C. Mascaux, 2018 .

Application of clinical trial inclusion criteria to clinical practice patients to quantify the burden of CNS metastases on health-related quality of life and healthcare resource use in patients with NSCLC.

P. Tomasini, N. Khan, S. Hammerschmidt, 2020, Lung cancer.

Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100

C. Dooms, R. Govindan, S. Ramalingam, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early ctDNA dynamics and efficacy of lorlatinib in patients with treatment-naïve, advanced, ALK-positive non-small cell lung cancer.

A. Shaw, C. Chiu, P. Tomasini, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

27P Durability of efficacy and safety with selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC)

A. Drilon, P. Tomasini, B. Besse, 2022, Annals of Oncology.

1273P Durvalumab (D) compared to maintenance chemotherapy (SoC) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): Results from the randomized SAFIR02 LUNG-IMMUNO trial

I. Bièche, J. Adam, J. Soria, 2020 .

Prognostic and predictive effects of TP53 mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).

M. Tsao, F. Shepherd, S. Kamel‐Reid, 2016 .

Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer

J. Galon, J. Adam, P. Tomasini, 2023, EBioMedicine.

“I think it’s a bit early for now”: impact of psychological factors on drafting advance directives among cancer patients

L. Dany, P. Cannone, F. Barlesi, 2018, Journal of psychosocial oncology.

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

N. Girard, D. Planchard, J. Mazières, 2017, European Respiratory Journal.

Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS.

T. Jatkoe, S. Ou, E. Felip, 2023, Journal of Clinical Oncology.

Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid

F. Barlesi, P. Tomasini, L. Ouafik, 2018, Clinical chemistry and laboratory medicine.

[Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].

P. Tomasini, L. Greillier, S. Marco, 2011, Revue des maladies respiratoires.

Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer

F. Bertucci, P. Finetti, P. Tomasini, 2023, Journal of Translational Medicine.

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).

M. Tsao, F. Shepherd, S. Kamel‐Reid, 2017, Lung cancer.

Tumor relapse after thoracic surgery?

F. Barlesi, P. Tomasini, P. Thomas, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.

P. Tomasini, F. Guisier, R. Gervais, 2023, Lung cancer.

Abstract CT179: Telisotuzumab vedotin (teliso-v) monotherapy in patients with previously treated c-Met+advanced non-small cell lung cancer

D. Camidge, P. Tomasini, F. Moiseenko, 2021, Clinical Trials.

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).

J. Mazières, C. Mascaux, F. Barlesi, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Adrenal surgery for oligometastatic tumors improves survival in selected cases.

F. Barlesi, P. Tomasini, F. Sebag, 2017, Journal of visceral surgery.